184 related articles for article (PubMed ID: 1466089)
1. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group.
Aso Y; Akazan H
Urol Int; 1992; 49(3):125-9. PubMed ID: 1466089
[TBL] [Abstract][Full Text] [Related]
2. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group.
Aso Y; Akaza H; Kotake T; Tsukamoto T; Imai K; Naito S
Eur Urol; 1995; 27(2):104-9. PubMed ID: 7744150
[TBL] [Abstract][Full Text] [Related]
3. Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer.
Naito S; Koga H; Yamaguchi A; Fujimoto N; Hasui Y; Kuramoto H; Iguchi A; Kinukawa N;
J Urol; 2008 Feb; 179(2):485-90. PubMed ID: 18076918
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of superficial transitional cell bladder carcinoma. Long-term results of trial comparing transurethral resection alone and adjuvant chemotherapy with Doxorubicin].
Milonas D; Mickevicius J; Mickevicius R; Motiejūnas A; Sukys D; Gudinaviciene I
Medicina (Kaunas); 2002; 38 Suppl 1():79-83. PubMed ID: 12556642
[TBL] [Abstract][Full Text] [Related]
5. [Submucosal injection of anti-tumor drug on the prevention of Post-TUR-Bt recurrence].
Chen X; Wang B; Tian HZ; Gao JZ
Zhonghua Wai Ke Za Zhi; 2004 May; 42(10):580-2. PubMed ID: 15265397
[TBL] [Abstract][Full Text] [Related]
6. The role of adjunctive immunotherapy in superficial bladder cancer.
Fujita K
Cancer; 1987 Jun; 59(12):2027-30. PubMed ID: 3567865
[TBL] [Abstract][Full Text] [Related]
7. Intravesical therapy in superficial bladder cancer.
Witjes JA; Mulders PF; Debruyne FM
Urology; 1994 Feb; 43(2 Suppl):2-5; discussion 6. PubMed ID: 8116130
[TBL] [Abstract][Full Text] [Related]
8. The biology and treatment of superficial bladder cancer.
Torti FM; Lum BL
J Clin Oncol; 1984 May; 2(5):505-31. PubMed ID: 6427417
[TBL] [Abstract][Full Text] [Related]
9. A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer--intravesical thio-TEPA versus oral UFT.
Hirao Y; Okajima E; Ozono S; Samma S; Sasaki K; Hiramatsu T; Babaya K; Watanabe S; Maruyama Y
Cancer Chemother Pharmacol; 1992; 30 Suppl():S26-30. PubMed ID: 1394812
[TBL] [Abstract][Full Text] [Related]
10. Management and prognosis of transitional cell carcinoma superficial recurrence in muscle-invasive bladder cancer after bladder preservation.
Pieras E; Palou J; Salvador J; Rosales A; Marcuello E; Villavicencio H
Eur Urol; 2003 Aug; 44(2):222-5; discussoion 225. PubMed ID: 12875942
[TBL] [Abstract][Full Text] [Related]
11. [Ablative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Bladder cancer BCG Study Group].
Akaza H; Kameyama S; Kakizoe T; Kojima H; Koiso K; Aso Y; Niijima T
Nihon Hinyokika Gakkai Zasshi; 1992 Feb; 83(2):183-9. PubMed ID: 1556836
[TBL] [Abstract][Full Text] [Related]
12. Effects of local chemotherapy and immunotherapy on the recurrence and progression of superficial bladder cancer.
Novak R; Kern J; Fister H; Trnski D; Dimanovski J; Kraus O
Eur Urol; 1988; 14(5):367-70. PubMed ID: 3139417
[TBL] [Abstract][Full Text] [Related]
13. Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
Cervenakov I; Szoldova K; Mardiak J; Chovan D; Mala M; Slavov D
Bratisl Lek Listy; 2000; 101(6):317-20. PubMed ID: 11039202
[TBL] [Abstract][Full Text] [Related]
14. Immunoprophylaxis of superficial bladder cancer: a prospective and randomized comparison of oral versus intravesical Bacillus Calmette-Guerin.
Netto Júnior NR; Levi d'Ancona CA; Claro JF; Ilari O
Arch Esp Urol; 1991 Oct; 44(8):1025-8. PubMed ID: 1796850
[TBL] [Abstract][Full Text] [Related]
15. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.
Saika T; Tsushima T; Nasu Y; Miyaji Y; Saegusa M; Takeda K; Kumon H
World J Urol; 2010 Aug; 28(4):413-8. PubMed ID: 20054553
[TBL] [Abstract][Full Text] [Related]
16. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
17. Intravesical therapy: does it affect the natural history of superficial bladder cancer?
Lamm DL; Griffith JG
Semin Urol; 1992 Feb; 10(1):39-44. PubMed ID: 1565903
[No Abstract] [Full Text] [Related]
18. Efficacy of escalating doses of intravesical interferon alpha-2b in reducing recurrence rate and progression in superficial transitional cell carcinoma.
Giannakopoulos S; Gekas A; Alivizatos G; Sofras F; Becopoulos T; Dimopoulos C
Br J Urol; 1998 Dec; 82(6):829-34. PubMed ID: 9883220
[TBL] [Abstract][Full Text] [Related]
19. [Short-term intravesical instillation of pirarubicin (THP) in prophylactic treatment after transurethral resection of superficial bladder tumor].
Kuroda K; Ishii N; Fukasawa K; Shirai M; Tajima M; Matsushima M; Miura K; Takanami M; Matsuhashi M; Kuwabara T; Matsumoto H; Sugita M
Hinyokika Kiyo; 1998 Aug; 44(8):547-52. PubMed ID: 9783189
[TBL] [Abstract][Full Text] [Related]
20. [Mitoxantrone chemoprophylaxis for multirecurrent multifocal superficial bladder tumours: results of a phase 2 controlled study].
Bassi PF; Spinadin R; Carando R; Dal Moro F; Abatangelo G; Piazza N; Tavolini IM
Arch Ital Urol Androl; 2003 Dec; 75(4):202-4. PubMed ID: 15005494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
